Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Hut 8 Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $295.89 (market cap $8.04B), while Hut 8 Corp trades at $103.69 (market cap $11.07B). The key difference: Hut 8 Corp is the larger of the two by market cap, and Hut 8 Corp is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | HUT | |
|---|---|---|
Market Cap | $8.04B | $11.07B |
Sector | Health | Technology |
52-Week High | $339.75 | $133.02 |
52-Week Low | $241.71 | $19.45 |
Enterprise Value | $7.85B | $11.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
HUT trades at $99.17, down 2.98% today, with a bearish technical signal. The company shows strong revenue growth potential but deep losses, with a net income margin of -109.77% in 2025. Recent news highlights its pivot to AI infrastructure, securing $16.8 billion in contracted revenue and closing a $4.25 billion investment-grade bond for data center projects.
Outlook is mixed: analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent negative cash flow from operations pose risks. The stock's near-term direction hinges on Q2 2026 earnings results and execution of its infrastructure expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
